- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.03. | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.03. | TD Cowen reiterates buy on Apogee Therapeutics stock | 2 | Investing.com | ||
| APOGEE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.03. | Apogee Therapeutics: Steigende Verluste trotz wachsender Marktchancen | 3 | IT BOLTWISE | ||
| 03.03. | Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial | 1 | Benzinga.com | ||
| 03.03. | Jefferies lifts Apogee Therapeutics stock target to $86, maintains buy | 4 | Investing.com | ||
| 03.03. | Apogee Therapeutics reports FY results | 3 | Seeking Alpha | ||
| 03.03. | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.03. | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | 200 | GlobeNewswire (Europe) | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen | |
| 03.03. | Apogee Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 03.03. | Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990) | 120 | GlobeNewswire (Europe) | Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head... ► Artikel lesen | |
| 03.03. | Apogee Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 03.02. | Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis | 187 | GlobeNewswire (Europe) | Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.... ► Artikel lesen | |
| 03.02. | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.01. | Here's Why Apogee Therapeutics, Inc. (APGE) Will Double in 2025 | 2 | Insider Monkey | ||
| 10.12.24 | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions | 205 | GlobeNewswire (Europe) | Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus... ► Artikel lesen | |
| 10.12.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.24 | Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day | 6 | GlobeNewswire (USA) | ||
| 02.12.24 | Apogee Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.11.24 | Apogee Therapeutics Announces Agenda for Virtual R&D Day | 2 | GlobeNewswire (USA) | ||
| 18.11.24 | Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 53,50 | 0,00 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
| BEAM THERAPEUTICS | 20,170 | 0,00 % | Cathie Wood's ARK Sells Adaptive Biotech, Buys Beam Therapeutics Stock | ||
| SPRINGWORKS THERAPEUTICS | 44,990 | 0,00 % | EQS-Adhoc: Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme | EQS-Ad-hoc: Merck KGaA / Schlagwort(e): Firmenübernahme
Merck KGaA: Merck bestätigt weit fortgeschrittene Gespräche mit SpringWorks Therapeutics, Inc. zu möglicher Übernahme
24.04.2025 /... ► Artikel lesen | |
| ARCELLX | 63,97 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 36,680 | 0,00 % | Summit Therapeutics: Überzeugende Daten - BioNTech gibt ebenfalls mächtig Gas | Die Biotech-Gesellschaft Summit Therapeutics, mit einem Börsenwert von gut 20 Milliarden Dollar kein kleines Unternehmen mehr, kann am Mittwoch erneut über vielversprechende Daten zum großen Hoffnungsträger... ► Artikel lesen | |
| QIAGEN | 37,525 | -0,23 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
| BIONTECH | 103,40 | +1,17 % | BioNTech Aktie: Leichte Erholung im Fokus | BioNTech zeigt technische Erholungssignale trotz schwieriger Bewertung. Analysten halten an Kaufempfehlungen fest - wohin steuert die Aktie? Die BioNTech-Aktie zeigt nach turbulenten Wochen erste Anzeichen... ► Artikel lesen | |
| EVOTEC | 7,290 | -0,74 % | Deutsche Telekom, Evotec, Meta Platforms, Rheinmetall, Siemens Energy, Talanx - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,400 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) | - Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| VERA THERAPEUTICS | 23,470 | 0,00 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 6,290 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,750 | 0,00 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 | ||
| ADMA BIOLOGICS | 22,340 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 3,190 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 5,100 | 0,00 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development... ► Artikel lesen |
APOGEE THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 37,040 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu APOGEE THERAPEUTICS INC finden Sie auf Wallstreet Online.
